Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TRK-950,Paclitaxel,Ramucirumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Bolt Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Bolt Biotherapeutics Updates Cancer Immunotherapy Co-Development with Toray
Details : The collaboration aims to develop TRK-950, an Caprin-1 designed to target multiple solid tumor types. Currently, it is being evaluated for the treatment of gastric cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 11, 2025
Lead Product(s) : TRK-950,Paclitaxel,Ramucirumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Bolt Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
Details : The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Details : TRK-950 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stomach Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 15, 2023
A Study of TRK-950 in Patients With Advanced Solid Tumors
Details : TRK-950 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 21, 2022
Details : TRK-750 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 25, 2020
Details : TRK-950 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 13, 2019
Lead Product(s) : TRK-250
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRK-250 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2018
Lead Product(s) : TRK-250
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750
Details : TRK-750 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 17, 2017
Lead Product(s) : TRK-700
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam
Details : TRK-700 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 03, 2017
Lead Product(s) : TRK-700
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus
Details : TRK-820 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pruritus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 23, 2016
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
